chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Vaccination site pain
Clinical narrative: Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Moderate injection site tenderness (tenderness with movement)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.            No concomitant medications were reported.  It was reported that the patient had experienced Moderate injection site pain interfering with activity, Moderate injection site tenderness (tenderness with movement), Mild fatigue and no interference with activity and Mild muscle pain and no interference with activity anytime during the 2 days after your COVID-19 vaccination, which occurred on Saturday, 16-Dec-2023 and Sunday, 17-Dec-2023.  No treatment medications were reported.  The Health Authority Subject ID was reported as: 52769-18203. The Database Subject ID was reported as: 5470047.   This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:Master case
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Malaise, Myalgia
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and PYREXIA (Mild fever (100.4 to 101.2 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).         Concomitant medication was not reported.  Patient had experienced the events anytime during the 2 days after your COVID-19 vaccination, which occurred on Tuesday, 19-Dec-2023 and Wednesday, 20-Dec-2023. Treatment medication was not reported.  The Database Subject ID was reported as 5472849. The Health Authority Subject ID was reported as 68077-10926.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and PYREXIA (Mild fever (100.4 to 101.2 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and HEADACHE (Headache and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).         Concomitant medication was not reported.  Patient had experienced the events anytime during the 2 days after your COVID-19 vaccination, which occurred on Tuesday, 19-Dec-2023 and Wednesday, 20-Dec-2023. Treatment medication was not reported.  The Database Subject ID was reported as 5472849. The Health Authority Subject ID was reported as 68077-10926.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Moderate injection site pain interfering with activity/ Moderate injection site tenderness (tenderness with movement); Mild injection site redness; Moderate injection site swelling; Mild fatigue and no interference with activity; Moderate muscle pain with some interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity). At the time of the report, VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity) outcome was unknown.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       No concomitant medication was reported.   Patient had experienced vaccination site pain, vaccination site erythema, vaccination site swelling, fatigue and myalgia anytime during the 2 days after COVID-19 vaccination, which occurred on Saturday, 16-Dec-2023 and Sunday, 17-Dec-2023.    No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:Patient 4
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity) outcome was unknown.            No concomitant medication was reported.   Patient had experienced vaccination site pain anytime during the 2 days after COVID-19 vaccination, which occurred on Sunday, 17-Dec-2023 and Monday, 18-Dec-2023.   The Subject ID was reported.   The Subject ID was reported.   No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Myalgia, Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), FATIGUE (Mild fatigue and no interference with activity) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: No fever (< 100.4 °F).         No concomitant medication was reported.    Patient had experienced events anytime during the 2 days after your COVID-19 vaccination, which occurred on Wednesday, Dec 20, 2023 and Thursday, Dec 21, 2023. No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient no
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Malaise, Myalgia, Pyrexia
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest); Significant injection site redness; Moderate injection site swelling; Mild fever (100.4 to 101.2 degree F); Severe fatigue with significant interference with activity; Moderate muscle pain with some interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and PYREXIA (Mild fever (100.4 to 101.2 degree F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 degree F)), FATIGUE (Severe fatigue with significant interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 degree F)), FATIGUE (Severe fatigue with significant interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 degree F).         No concomitant medications were reported. Patient had experienced the symptoms during the 2 days after COVID-19 vaccination, which occurred on Wednesday, Dec 20, 2023, and Thursday, Dec 21, 2023. No treatment medications were reported. The Subject ID was reported and the Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 61 out of 87
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest); Significant injection site redness; Moderate injection site swelling; Mild fever (100.4 to 101.2 degree F); Severe fatigue with significant interference with activity; Moderate muscle pain with some interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling) and PYREXIA (Mild fever (100.4 to 101.2 degree F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 degree F)), FATIGUE (Severe fatigue with significant interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Moderate injection site pain interfering with activity/Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Moderate injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 degree F)), FATIGUE (Severe fatigue with significant interference with activity) and MYALGIA (Moderate muscle pain with some interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 degree F).         No concomitant medications were reported. Patient had experienced the symptoms during the 2 days after COVID-19 vaccination, which occurred on Wednesday, Dec 20, 2023, and Thursday, Dec 21, 2023. No treatment medications were reported. The Subject ID was reported and the Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 61 out of 87
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)) outcome was unknown.            No concomitant medications were reported.  Patient had experienced the symptoms during the 2 days after COVID-19 vaccination, which occurred on Tuesday, Dec 19, 2023, and Wednesday, Dec 20, 2023  No treatment medications were reported.      This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Myalgia, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement); Moderate injection site swelling; Mild muscle pain and no interference with activity; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE SWELLING (Moderate injection site swelling) and MYALGIA (Mild muscle pain and no interference with activity) in a  patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE SWELLING (Moderate injection site swelling) and MYALGIA (Mild muscle pain and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE SWELLING (Moderate injection site swelling) and MYALGIA (Mild muscle pain and no interference with activity) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: No fever (< 100.4 °F).          Concomitant medication was not reported. Also, it has been reported that the symptom of vaccination site pain, vaccination site swelling, and myalgia were experienced anytime during the 2 days after vaccination on either Tuesday, Dec 19, 2023, or Wednesday, Dec 20, 2023 Further it has been reported that patient did not have symptom of injection site redness, fever, fatigue, malaise or feeling sick, Joint pain, nausea or vomiting and headache. No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:Pateint 49 out of 49
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Mild injection site tenderness (tender to touch); This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site tenderness (tender to touch)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site tenderness (tender to touch)). At the time of the report, VACCINATION SITE PAIN (Mild injection site tenderness (tender to touch)) outcome was unknown.            The Health Authority Subject ID was reported as 78699-13911 and Database  ID was reported as 5473815.  Concomitant medication was not reported.  Also, it has been reported that the symptom of vaccination site pain was experienced anytime during the 2 days after vaccination on either Sunday, Dec 17, 2023, or Monday, Dec 18, 2023.  No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild fatigue and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)) and FATIGUE (Mild fatigue and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)) and FATIGUE (Mild fatigue and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)) and FATIGUE (Mild fatigue and no interference with activity) outcome was unknown.            The subject ID was reported and auto-cruitment subject ID was reported. Concomitant medication was not reported. It has been reported that the symptom of vaccination site pain and fatigue were experienced anytime during the 2 days after vaccination on either Wednesday, Dec 20, 2023, or Thursday, Dec 21, 2023. No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient
Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Vaccination site erythema, Vomiting
Clinical narrative: Mild injection site redness; Mild muscle pain and no interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE ERYTHEMA (Mild injection site redness), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE ERYTHEMA (Mild injection site redness), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting). At the time of the report, VACCINATION SITE ERYTHEMA (Mild injection site redness), MYALGIA (Mild muscle pain and no interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) outcome was unknown.            Patient subject ID was reported as 94049-83856 and database  ID was reported as 5473767.  Concomitant medication was not reported.  Also, it has been reported that the symptom of vaccination site pain and fatigue were experienced anytime during the 2 days after vaccination on either Sunday, Dec 17, 2023, or Monday, Dec 18, 2023.  No treatment medications provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Master case
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Headache, Pyrexia, Vaccination site erythema
Clinical narrative: Mild injection site redness; Mild injection site swelling ; Mild fever (100.4 to 101.2 °F) ; Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ; Mild fatigue and no interference with activity ; Headache and no interference with activity ; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling ), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ) and FATIGUE (Mild fatigue and no interference with activity ) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling ), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ), FATIGUE (Mild fatigue and no interference with activity ) and HEADACHE (Headache and no interference with activity ). At the time of the report, VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling ), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ), FATIGUE (Mild fatigue and no interference with activity ) and HEADACHE (Headache and no interference with activity ) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).         Subject ID was reported and Subject ID was reported.  No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Tuesday, Dec 19, 2023 and Wednesday, Dec 20, 2023.  No treatment information was provided.  This case contains information of 71st out of 87 patients reported by same reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 71
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild injection site redness; Mild injection site swelling ; Mild fever (100.4 to 101.2 °F) ; Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ; Mild fatigue and no interference with activity ; Headache and no interference with activity ; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling ), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ) and FATIGUE (Mild fatigue and no interference with activity ) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling ), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ), FATIGUE (Mild fatigue and no interference with activity ) and HEADACHE (Headache and no interference with activity ). At the time of the report, VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling ), PYREXIA (Mild fever (100.4 to 101.2 °F) ), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch) ), FATIGUE (Mild fatigue and no interference with activity ) and HEADACHE (Headache and no interference with activity ) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).         Subject ID was reported and Subject ID was reported.  No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Tuesday, Dec 19, 2023 and Wednesday, Dec 20, 2023.  No treatment information was provided.  This case contains information of 71st out of 87 patients reported by same reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 71
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Myalgia, Vaccination site erythema
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site redness; Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Joint pain and no interference with activity; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and ARTHRALGIA (Joint pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache and no interference with activity) outcome was unknown.            No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Saturday, Dec 16, 2023 and Sunday, Dec 17, 2023.  No treatment information was provided.  The Subject ID was reported and Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site redness; Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Joint pain and no interference with activity; Headache and no interference with activity; This spontaneous case was reported by a non-health professional and describes the occurrence of VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity) and ARTHRALGIA (Joint pain and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache and no interference with activity). At the time of the report, VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache and no interference with activity) outcome was unknown.            No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Saturday, Dec 16, 2023 and Sunday, Dec 17, 2023.  No treatment information was provided.  The Subject ID was reported and Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756177 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756177:same reporter
Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Fatigue, Headache, Malaise, Myalgia
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement); Mild injection site redness; Mild injection site swelling; Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Joint pain and no interference with activity; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and FATIGUE (Mild fatigue and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.            No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Wednesday, Dec 20, 2023 and Thursday, Dec 21, 2023.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 46 out of 87
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Mild malaise/feeling sick and no interference with activity; Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement); Mild injection site redness; Mild injection site swelling; Mild fatigue and no interference with activity; Mild muscle pain and no interference with activity; Joint pain and no interference with activity; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and FATIGUE (Mild fatigue and no interference with activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Mild malaise/feeling sick and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/ Moderate injection site tenderness (tenderness with movement)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), FATIGUE (Mild fatigue and no interference with activity), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.            No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Wednesday, Dec 20, 2023 and Thursday, Dec 21, 2023.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Patient 46 out of 87